Work

JAVELIN: avelumab another spear to fight urothelial carcinoma

Year: 2017

Type: article

Source: The Lancet Oncology

DOI: 10.1016/s1470-2045(17)30901-4

Authors: Aly-Khan A Lalani, Bradley A McGregor, Guru P Sonpavde, Toni K Choueiri

Institutions: Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: Amgen, Bristol-Myers Squibb, Pfizer, Bayer, GlaxoSmithKline, Merck, Novartis, Exelixis, National Comprehensive Cancer Network, Janssen Biotech

OpenAlex ID: W2772506832

FWCI: 0.216

Cites: 10

Cited by: 2

Related to: 10